United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen pharma ltd - ascorbic acid - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen pharma ltd - ascorbic acid - oral tablet - 500mg

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - methamphetamine hydrochloride (unii: 997f43z9cv) (methamphetamine - unii:44ral3456c) - methamphetamine hydrochloride 5 mg - attention deficit disorder with hyperactivity: methamphetamine hydrochloride tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. in patients known to be hypersensitive to amphetamine, or other components of methamphetamine hydrochloride tablets, hypersensitivity reactions such as angioedema and anaphylactic reactions have been re

United States - English - NLM (National Library of Medicine)

mayne pharma commercial llc - methamphetamine hydrochloride (unii: 997f43z9cv) (methamphetamine - unii:44ral3456c) - methamphetamine hydrochloride 5 mg - methamphetamine hydrochloride tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. in patients known to be hypersensitive to amphetamine, or other components of methamphetamine hydrochloride tablets. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetami

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - ascorbic acid - not applicable - 1mg/1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m loveridge ltd - ascorbic acid - not applicable - 1mg/1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - ascorbic acid - not applicable - 1mg/1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - ascorbic acid - not applicable - 1mg/1mg

Canada - English - Health Canada

stanley pharmaceuticals, a division of vita health products inc. - ascorbic acid; sodium ascorbate - tablet - 100mg; 168.75mg - ascorbic acid 100mg; sodium ascorbate 168.75mg - vitamin c

Canada - English - Health Canada

stanley pharmaceuticals, a division of vita health products inc. - ascorbic acid; sodium ascorbate - tablet - 50mg; 56.2mg - ascorbic acid 50mg; sodium ascorbate 56.2mg - vitamin c